At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. In this latest episode, Thomas speaks with Vito Palombella, Chief Scientific Officer at Surface Oncology. You… Read More
The College of American Pathologists (CAP) and American Society of Clinical Oncology (ASCO) have reaffirmed the Human Epidermal Growth Factor Receptor 2 (HER2) Breast Cancer Testing Guidelines, reducing confusion over terminology for reporting HER2 results. The recent clinical trial for metastatic breast cancer patients (DESTINY-Breast04) found that a treatment traditionally… Read More
At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW's Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. Thomas speaks with Andreas Bader, Chief Scientific Officer at Triumvira Immunologics. MT: Where do you work, and… Read More
At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. In this latest episode, Thomas speaks with Andreas Bader, Chief Scientific Officer at Triumvira Immunologics. You… Read More
AstraZeneca UK announced that Lynparza (olaparib) is recommended by the National Institute for Health and Care Excellence (NICE) for maintenance treatment of BRCA-mutated relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer in adults who have had two or more courses of platinum-based chemotherapy. BRCA1 and BRCA2 are… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. There has been some interesting news related to clinical trials this week, with the announcement that… Read More
At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. In this latest episode, Thomas speaks with Dennis Brown, Chief Scientific Officer at Kintara Therapeutics. You… Read More
At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida, DDW's Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. Thomas speaks with Dennis Brown, Chief Scientific Officer at Kintara Therapeutics. You can also listen to these… Read More
Immutep revealed positive final data from Part C of the TACTI-002 Phase II trial at the ASCO 2023 Annual Meeting in Chicago, US. The trial evaluated eftilagimod alpha (efti), a soluble LAG-3 protein and first-in-class MHC Class II agonist, in combination with MSD’s (Merck) anti-PD-1 therapy Keytruda… Read More
News round-up for 5-9 June by DDW Digital Content Editor Diana Spencer. There has been some interesting news related to clinical trials this week, with the announcement that the FDA has published draft guidance to modernise the design and conduct of studies, and the failure of… Read More
RemeGen announced the latest clinical research results on disitamab vedotin (RC48) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Researchers tested disitamab vedotin and toripalimab in combination on patients diagnosed with locally advanced or metastatic urothelial carcinoma (la/mUC). The objective of the study… Read More
Ground-breaking data from several key cancer trials were announced at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. ADAURA Phase III trial The trial assessed Tagrisso (osimertinib) as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated… Read More
Biotech company Shasqi and Johnson & Johnson have entered into a research collaboration to develop new cancer therapies. Shasqi’s Click Activated Protodrugs Against Cancer (CAPAC) platform relies on chemistry for activation of drugs at the tumour. The platform is made up of a tumour-targeting agent and… Read More
Positive primary endpoint data from Novartis’ pivotal Phase III NATALEE trial has been presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Data showed that Kisqali (ribociclib) plus endocrine therapy (ET), compared to ET alone, lowered the risk of cancer recurrence by 25.2%… Read More
Janssen has presented new data from across its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Talquetamab Talquetamab is an investigational GPRC5D-directed bispecific antibody currently in clinical development. Updated results from the Phase II MonumenTAL-1 study show that… Read More
DDW’s Diana Spencer chats to Macomics’ co-founder and VP Immunology Dr Luca Cassetta about the company’s approach to tumour suppression and the challenges of launching a new business in early 2020. DS: Congratulations on the publication of your discoveries in Nature Reviews Cancer. Your studies focus on tumour associated macrophages (TAMs). What role do they… Read More
